{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = 2-[2-[4-[(''E'')-3,3,3-trifluoro-1,2-diphenylprop-1-enyl]phenoxy]ethylamino]ethanol
| image = Panomifene skeletal.svg
| width = 150px

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = 

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = 
| CAS_number = 77599-17-8
| CAS_supplemental = 
| class = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 3033654
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 2298282
| UNII = GCW5E728OC
| KEGG = 
| ChEBI = 
| ChEMBL = 2105273

<!--Chemical data-->
| C=25 | H=24 | F=3 | N=1 | O=2
| molecular_weight = 427.467 g/mol
| SMILES = C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\C(F)(F)F)/C3=CC=C(C=C3)OCCNCCO
| StdInChI_Ref = 
| StdInChI = 1S/C25H24F3NO2/c26-25(27,28)24(21-9-5-2-6-10-21)23(19-7-3-1-4-8-19)20-11-13-22(14-12-20)31-18-16-29-15-17-30/h1-14,29-30H,15-18H2/b24-23+
| StdInChIKey_Ref = 
| StdInChIKey = MHXVDXXARZCVRK-WCWDXBQESA-N
| synonyms = GYKI-13504; EGIS-5650
}}

'''Panomifene''' ([[International Nonproprietary Name|INN]]) (former developmental code names '''GYKI-13504''', '''EGIS-5650''') is a [[nonsteroidal]] [[selective estrogen receptor modulator]] (SERM) of the [[triphenylethylene]] group related to [[tamoxifen]] that was under development as an [[antineoplastic agent]] by [[Egis Pharmaceuticals]] and [[IVAX Drug Research Institute]] in the 1990s for the treatment of [[breast cancer]] but was not marketed.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA930|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=930–}}</ref><ref name="AdisInsight">http://adisinsight.springer.com/drugs/800002425</ref><ref name="OettelSchillinger2012a">{{cite book|author1=Michael Oettel|author2=Ekkehard Schillinger|title=Estrogens and Antiestrogens I: Physiology and Mechanisms of Action of Estrogens and Antiestrogens|url=https://books.google.com/books?id=0BfrCAAAQBAJ&pg=PA60|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-58616-3|pages=60–}}</ref><ref name="OettelSchillinger2012b">{{cite book|author1=Michael Oettel|author2=Ekkehard Schillinger|title=Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen|url=https://books.google.com/books?id=wBvyCAAAQBAJ&pg=PA292|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-60107-1|pages=292–}}</ref><ref name="DixneufBruneau2014">{{cite book|author1=Pierre H. Dixneuf|author2=Christian Bruneau|title=Ruthenium in Catalysis|url=https://books.google.com/books?id=sjndBAAAQBAJ&pg=PA385|date=18 October 2014|publisher=Springer|isbn=978-3-319-08482-4|pages=385–}}</ref><ref name="pmid9328614">{{cite journal | vauthors = Borvendég J, Hermann I, Csuka O | title = Antiestrogens, antiandrogens | journal = Acta Physiol Hung | volume = 84 | issue = 4 | pages = 405–6 | year = 1996 | pmid = 9328614 | doi = | url = }}</ref> It reached [[Phases of clinical research#Phase II|phase II]] [[clinical trial]]s before development was terminated.<ref name="AdisInsight" /> The drug was described in 1981.<ref name="Elks2014" />

==References==
{{Reflist|2}}

==External links==
* [http://adisinsight.springer.com/drugs/800002425 Panomifene - AdisInsight]


{{Estrogen receptor modulators}}

[[Category:Abandoned drugs]]
[[Category:Alcohols]]
[[Category:Amines]]
[[Category:Hormonal antineoplastic drugs]]
[[Category:Trifluoromethyl compounds]]
[[Category:Selective estrogen receptor modulators]]
[[Category:Triphenylethylenes]]


{{antineoplastic-drug-stub}}